Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.55 |
| ▸ | NPC1 | O15118 | 2/20 | 0.55 |
| ▸ | RAB9A | P51151 | 2/20 | 0.55 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26633940 | 0.92 | SMN1; SMN2 (0.55) | SMN1; SMN2NPC1RAB9AMCHR1HRH3 | |
| SCHEMBL26633697 | 0.90 | SMN1; SMN2 (0.53) | SMN1; SMN2NPC1RAB9AMCHR1HRH3 | |
| SCHEMBL26633693 | 0.90 | SMN1; SMN2 (0.53) | SMN1; SMN2NPC1RAB9AMCHR1HRH3 | |
| SCHEMBL26633886 | 0.89 | SMN1; SMN2 (0.52) | SMN1; SMN2NPC1RAB9AMCHR1HRH3 | |
| SCHEMBL26633914 | 0.88 | NPC1 (0.51) | SMN1; SMN2NPC1RAB9AMCHR1HRH3 | |
| SCHEMBL24011436 | 0.88 | SMN1; SMN2 (0.63) | SMN1; SMN2NPC1RAB9AMCHR1HRH3 | |
| SCHEMBL26633731 | 0.88 | SMN1; SMN2 (0.53) | SMN1; SMN2NPC1RAB9AMCHR1HRH3 | |
| SCHEMBL30306687 | 0.87 | NPC1 (0.54) | SMN1; SMN2NPC1RAB9AMCHR1HRH3 | |
| SCHEMBL26633750 | 0.87 | NPC1 (0.54) | SMN1; SMN2NPC1RAB9AMCHR1HRH3 | |
| SCHEMBL26633729 | 0.87 | SMN1; SMN2 (0.49) | SMN1; SMN2NPC1RAB9AMCHR1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348369-A1 | NAMPT MODULATORS | CYTOKINETICS, INC. | 2023-11-02 | — | — | US | disclosed |
| US-20230348369-A1 | NAMPT MODULATORS | CYTOKINETICS, INC. | 2023-11-02 | — | — | US | disclosed |
| US-20230348369-A1 | NAMPT MODULATORS | CYTOKINETICS, INC. | 2023-11-02 | — | — | US | disclosed |
| CN-115843295-A | NAMPT modulators | 赛特凯恩蒂克公司 | 2023-03-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348369-A1 | NAMPT MODULATORS | NAMPT, NNT, NAPRT | SMN1; SMN2 610/4885NPC1 128/4885RAB9A 814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.